Asia-Pacific Human Insulin Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Market Size (2024) | USD 7.48 Billion |
| Market Size (2029) | USD 8.48 Billion |
| CAGR (2024 - 2029) | 2.54 % |
| Market Concentration | High |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Asia-Pacific Human Insulin Market Analysis
The Asia - Pacific Human Insulin Market size is estimated at USD 7.48 billion in 2024, and is expected to reach USD 8.48 billion by 2029, growing at a CAGR of 2.54% during the forecast period (2024-2029).
During the COVID-19 crisis, the Asia-Pacific diabetes market saw a gradual growth in demand for diabetic medications. According to a 2021 BeatO research on 800 participants, patients with COVID-19 and pre-existing diabetes suffered blood glucose level changes, resulting in a significant need for advanced diabetic medicines. To mitigate the disastrous impact of COVID-19, Novo Nordisk established a new social responsibility plan to combat diabetes, intending to provide patients in every nation with access to affordable diabetic care.
Diabetes patients, particularly those with Type 2 diabetes, have increased rapidly in Asian nations during the last few decades. Developing nations account for more than 70% of the worldwide diabetes population. The Asia-Pacific region is expected to develop significantly due to an aging population and rising diabetes prevalence, mostly due to increased stress, sedentary lifestyles, smoking, and excessive alcohol intake, which raises the body's sugar levels. Furthermore, the region's production base of key anti-diabetic medicine businesses aided market expansion. However, one of the primary constraining factors for the industry is the rising cost of pharmaceuticals.
The genetic factor is one of the primary reasons for the rapid spread of the disease. Sedentary lifestyles and obesity are the other factors responsible for the high prevalence of the disease. Although insulin has been used for treating diabetes for over 90 years, more than half of those who need insulin today still cannot afford and access it due to the high cost of the product.
Asia-Pacific Human Insulin Market Trends
Surge in APAC Diabetic Population is driving the market in forecast period
There would be a massive surge in the diabetic population in the Asia-Pacific region. The burden of diabetes is increasing, and it is expected to grow at a high rate in the Asia-Pacific region. The Asia-Pacific region dominates the diabetes market globally, contributing to 60% of the diabetes population. China and India have the highest diabetes population, especially type 2.
China has over 11% of its population suffering from diabetes, and in India, 5% suffers from diabetes. All Type 1 diabetes patients and a limited number of Type 2 diabetes patients require daily insulin injections as part of their treatment.
Poor healthcare infrastructure and utilization and lack of awareness about the disease in other countries of Asia-Pacific have complicated its prevalence. Furthermore, in these areas, most cases are uncontrolled or even undiagnosed until patients get symptoms of complications. Factors such as lack of awareness about the disease, unbalanced nutrition, and inadequate healthcare infrastructure and utilization are restraining the insulin market in the region.
As of 2022, the prevalence rates for diabetes ranged from 12% to 19% of the population in several countries in the region. Therefore, owing to the factors above, the growth of the studied Market is anticipated in the Market.
China dominates the Asia-Pacific Human Insulin Market
China is anticipated to hold the largest market share and is expected to maintain its dominant position during the forecast period, owing to huge patient pools and the ease in the regulatory process for insulin biosimilar drugs in the country. The incidence of type-2 diabetes (T2D) has rapidly increased over the recent decade, and T2D has become a leading public health challenge in China.
There is a considerable rise in the biosimilar drugs market in the Asia-Pacific, and China's Gan&Lee Basalin occupies almost 40% of the overall Glargine market. The country is witnessing a significant increase in generic drug manufacturers. Furthermore, the leading global players in the market studied faced intense competition from the regional players.
Diabetes is becoming an increasingly common condition in China. According to World Diabetes Day in 2030, there will be 643 million diabetics worldwide, the greatest amount. According to health professionals, urbanization, improving living standards, and an aging population are the main factors contributing to this spike. So, it is anticipated that during the coming several years, China's market for diabetes care will expand steadily.
Diabetes is a chronic illness that develops when the body either cannot use the insulin the pancreas makes effectively or cannot create any or enough of it. Type 1, Type 2 (the most prevalent kind), and gestational diabetes are the three primary subtypes of diabetes. Several early indications and symptoms of diabetes can be undetectable or modest. Almost two-thirds of diabetic patients in China were unaware of their illness and did not take any preventative steps. Diabetes that is left untreated can lead to major health issues like cardiovascular disease, chronic renal disease, and stroke.
All persons with type 1 diabetes, some people with type 2 diabetes, and some women who are pregnant who have diabetes need an ongoing supply of insulin. Novo Nordisk, the market leader in human insulin, controls the 20 billion yuan market for its analogs in China.
Asia-Pacific Human Insulin Industry Overview
The Asia-Pacific Human Insulin Market is highly consolidated, with three major manufacturers having a large market share. However, many local companies have brought biosimilar insulin at a much lower price. Mergers and acquisitions between the players in the recent past helped the companies strengthen their market presence. Sandoz partnered with Gan&Lee for the commercialization of insulin developed by Gan&Lee. Sandoz will likely fully commercialize these medicines in the EU, the United States, Switzerland, Japan, South Korea, Canada, Australia, and New Zealand.
Asia-Pacific Human Insulin Market Leaders
-
Novo Nordisk
-
Eli Lilly
-
Sanofi
-
Biocon
-
Gan & Lee
*Disclaimer: Major Players sorted in no particular order
Asia-Pacific Human Insulin Market News
- September 2023: Meitheal Pharmaceuticals has secured the exclusive licensing rights from Tonghua Dongbao Pharmaceutical, a China-based company, to distribute three insulin biosimilars in the United States. These biosimilars consist of two rapid-acting insulins, insulin lispro and insulin aspart, as well as the long-acting insulin glargine. The parent company of Meitheal, Nanjing King-Friend Biochemical Pharmaceutical, has acquired these rights.
- March 2023: About three months after its approval for diabetes treatment, Hangzhou Zhongmei Huadong Pharma's Liraglutide Injection (Liluping) was also given the green light for obesity care.
Asia-Pacific Human Insulin Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Drivers
- 4.3 Restraints
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Suppliers
- 4.4.2 Bargaining Power of Consumers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products and Services
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 Drug
- 5.1.1 Insulin
- 5.1.1.1 Basal or Long Acting Insulins
- 5.1.1.1.1 Lantus (Insulin Glargine)
- 5.1.1.1.2 Levemir (Insulin Detemir)
- 5.1.1.1.3 Toujeo (Insulin Glargine)
- 5.1.1.1.4 Tresiba (Insulin Degludec)
- 5.1.1.1.5 Abasaglar (Insulin Glargine)
- 5.1.1.2 Bolus or Fast Acting Insulins
- 5.1.1.2.1 NovoRapid/Novolog (Insulin Aspart)
- 5.1.1.2.2 Humalog (Insulin Lispro)
- 5.1.1.2.3 Apidra (Insulin Glulisine)
- 5.1.1.2.4 FIASP (Insulin Aspart)
- 5.1.1.2.5 Admelog (Insulin Lispro)
- 5.1.1.3 Traditional Human Insulins
- 5.1.1.3.1 Novolin/Actrapid/Insulatard
- 5.1.1.3.2 Humilin
- 5.1.1.3.3 Insuman
- 5.1.1.4 Insulin Combinations
- 5.1.1.4.1 NovoMix (Biphasic Insulin Aspart)
- 5.1.1.4.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
- 5.1.1.4.3 Xultophy (Insulin Degludec and Liraglutide)
- 5.1.1.4.4 Soliqua/Suliqua (Insulin Glargine and Lixisenatide)
- 5.1.1.5 Biosimilar Insulins
- 5.1.1.5.1 Insulin Glargine Biosimilars
- 5.1.1.5.2 Human Insulin Biosimilars
-
5.2 Geography
- 5.2.1 Australia
- 5.2.2 China
- 5.2.3 India
- 5.2.4 Indonesia
- 5.2.5 Japan
- 5.2.6 Malaysia
- 5.2.7 Philippines
- 5.2.8 South Korea
- 5.2.9 Thailand
- 5.2.10 Vietnam
- 5.2.11 Rest of Asia-Pacific
6. MARKET INDICATORS
- 6.1 Type-1 Diabetic Population
- 6.2 Type-2 Diabetic Population
7. COMPETITIVE LANDSCAPE
-
7.1 Company Profiles
- 7.1.1 Novo Nordisk
- 7.1.2 Eli Lilly
- 7.1.3 Sanofi
- 7.1.4 Biocon
- 7.1.5 Gan & Lee
- 7.1.6 Wockhardt
- *List Not Exhaustive
-
7.2 Company Share Analysis
- 7.2.1 Novo Nordisk
- 7.2.2 Eli Lilly
- 7.2.3 Sanofi
- 7.2.4 Other Companies
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityAsia-Pacific Human Insulin Industry Segmentation
Regular insulin is a kind of medical short-acting insulin, sometimes referred to as neutral and soluble insulin. Type 1 diabetes, Type 2 diabetes, gestational diabetes, and diabetic complications such as diabetic ketoacidosis and hyperosmolar hyperglycemic states are all treated with it. Asia-Pacific Human Insulin Market is segmented into Product Type and by Asia-Pacific. The market provides the value (in USD) and Volume (in ml) for the above-mentioned segments.
| Drug | Insulin | Basal or Long Acting Insulins | Lantus (Insulin Glargine) |
| Levemir (Insulin Detemir) | |||
| Toujeo (Insulin Glargine) | |||
| Tresiba (Insulin Degludec) | |||
| Abasaglar (Insulin Glargine) | |||
| Drug | Insulin | Bolus or Fast Acting Insulins | NovoRapid/Novolog (Insulin Aspart) |
| Humalog (Insulin Lispro) | |||
| Apidra (Insulin Glulisine) | |||
| FIASP (Insulin Aspart) | |||
| Admelog (Insulin Lispro) | |||
| Drug | Insulin | Traditional Human Insulins | Novolin/Actrapid/Insulatard |
| Humilin | |||
| Insuman | |||
| Drug | Insulin | Insulin Combinations | NovoMix (Biphasic Insulin Aspart) |
| Ryzodeg (Insulin Degludec and Insulin Aspart) | |||
| Xultophy (Insulin Degludec and Liraglutide) | |||
| Soliqua/Suliqua (Insulin Glargine and Lixisenatide) | |||
| Drug | Insulin | Biosimilar Insulins | Insulin Glargine Biosimilars |
| Human Insulin Biosimilars | |||
| Geography | Australia | ||
| China | |||
| India | |||
| Indonesia | |||
| Japan | |||
| Malaysia | |||
| Philippines | |||
| South Korea | |||
| Thailand | |||
| Vietnam | |||
| Rest of Asia-Pacific |
Asia-Pacific Human Insulin Market Research FAQs
How big is the Asia - Pacific Human Insulin Market?
The Asia - Pacific Human Insulin Market size is expected to reach USD 7.48 billion in 2024 and grow at a CAGR of 2.54% to reach USD 8.48 billion by 2029.
What is the current Asia - Pacific Human Insulin Market size?
In 2024, the Asia - Pacific Human Insulin Market size is expected to reach USD 7.48 billion.
Who are the key players in Asia - Pacific Human Insulin Market?
Novo Nordisk, Eli Lilly, Sanofi, Biocon and Gan & Lee are the major companies operating in the Asia - Pacific Human Insulin Market.
What years does this Asia - Pacific Human Insulin Market cover, and what was the market size in 2023?
In 2023, the Asia - Pacific Human Insulin Market size was estimated at USD 7.29 billion. The report covers the Asia - Pacific Human Insulin Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Asia - Pacific Human Insulin Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Asia-Pacific Human Insulin Industry Report
Statistics for the 2024 Asia-Pacific Human Insulin market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Asia-Pacific Human Insulin analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
